Donna Weber

6.1k total citations · 1 hit paper
79 papers, 2.7k citations indexed

About

Donna Weber is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Donna Weber has authored 79 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Hematology, 49 papers in Molecular Biology and 34 papers in Oncology. Recurrent topics in Donna Weber's work include Multiple Myeloma Research and Treatments (67 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Treatment and Pharmacology (25 papers). Donna Weber is often cited by papers focused on Multiple Myeloma Research and Treatments (67 papers), Protein Degradation and Inhibitors (31 papers) and Cancer Treatment and Pharmacology (25 papers). Donna Weber collaborates with scholars based in United States, Greece and France. Donna Weber's co-authors include Raymond Alexanian, Kay Delasalle, Meletios Α. Dimopoulos, Maria Gavino, Αchilles Anagnostopoulos, James S. Robertson, James B. Stubbs, Kenneth F. Koral, J A Siegel and Darrell R. Fisher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Donna Weber

75 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates.

1999 443 citations Donna Weber et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donna Weber United States	23	1.8k	1.5k	1.2k	448	378	79	2.7k
Raymond Powles United Kingdom	10	2.2k 1.2×	1.4k 1.0×	1.1k 1.0×	129 0.3×	332 0.9×	14	2.5k
Daniel E. Bergsagel Canada	28	1.6k 0.9×	1.1k 0.8×	1.2k 1.0×	190 0.4×	382 1.0×	73	2.6k
David Irwin United States	28	2.5k 1.4×	2.5k 1.7×	2.2k 1.9×	112 0.3×	278 0.7×	66	4.2k
Jamie K. Waselenko United States	13	276 0.2×	505 0.3×	520 0.4×	876 2.0×	742 2.0×	21	2.1k
Silvia Brugnatelli Italy	22	338 0.2×	531 0.4×	635 0.5×	90 0.2×	155 0.4×	78	1.4k
Dusan Kotasek Australia	28	577 0.3×	448 0.3×	1.2k 1.0×	103 0.2×	147 0.4×	104	2.3k
Suneel Mundle United States	28	1.3k 0.7×	913 0.6×	560 0.5×	526 1.2×	398 1.1×	131	3.3k
Alessandra Larocca Italy	20	1.1k 0.6×	895 0.6×	719 0.6×	58 0.1×	159 0.4×	101	1.5k
Paula Rodríguez‐Otero Spain	29	2.0k 1.1×	1.7k 1.2×	1.7k 1.4×	576 1.3×	284 0.8×	181	3.4k
Ehab Atallah United States	24	1.2k 0.7×	649 0.4×	564 0.5×	80 0.2×	649 1.7×	175	2.1k

Countries citing papers authored by Donna Weber

Since Specialization

Citations

This map shows the geographic impact of Donna Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Weber more than expected).

Fields of papers citing papers by Donna Weber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Weber. The network helps show where Donna Weber may publish in the future.

Co-authorship network of co-authors of Donna Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Weber. A scholar is included among the top collaborators of Donna Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Weber. Donna Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Xin, Qing Ye, Robert Z. Orlowski, et al.. (2015). Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology & Oncology. 8(1). 74–74. 16 indexed citations

Cohen, Lorenzo, Ying Guo, Yuhong Zhou, et al.. (2014). Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. Journal of Hematology & Oncology. 7(1). 41–41. 47 indexed citations

Chanan‐Khan, Asher, Sagar Lonial, Donna Weber, et al.. (2012). Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. International Journal of Hematology. 96(2). 254–262. 13 indexed citations

Ishak, K. Jack, J. Jaime, Mark T. Drayson, et al.. (2011). Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma. Value in Health. 14(5). 672–678. 8 indexed citations

Lonial, Sagar, Adam D. Cohen, Jeffrey A. Zonder, et al.. (2011). The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood. 118(21). 2935–2935. 4 indexed citations

Richards, Tiffany & Donna Weber. (2010). Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology. 27(S1). 25–42. 9 indexed citations

Zangari, Maurizio, Guido Tricot, Fenghuang Zhan, et al.. (2009). Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. Journal of Clinical Oncology. 28(1). 132–135. 44 indexed citations

Campagnaro, Erica, Rima M. Saliba, Sergio Giralt, et al.. (2008). Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer. 112(7). 1617–1624. 33 indexed citations

Christoforidou, Anna, Rima M. Saliba, Patricia Williams, et al.. (2007). Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. Biology of Blood and Marrow Transplantation. 13(5). 543–549. 18 indexed citations

10.

Wang, Michael, Robert Knight, David S. Siegel, et al.. (2006). Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.. Blood. 108(11). 3553–3553. 14 indexed citations

11.

Anagnostopoulos, Αchilles, Ana Aleman, Gregory D. Ayers, et al.. (2004). Comparison of high‐dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 100(12). 2607–2612. 46 indexed citations

12.

Weber, Donna, Steven P. Treon, Christos Emmanouilides, et al.. (2003). Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology. 30(2). 127–131. 65 indexed citations

13.

Donato, Michèle L., Ana Aleman, Richard E. Champlin, et al.. (2003). High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma. Leukemia & lymphoma. 45(4). 755–759. 20 indexed citations

14.

Alexanian, Raymond, et al.. (2003). Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology. 40(4 Suppl 4). 3–7. 40 indexed citations

15.

Weber, Donna, et al.. (2002). Implementation of PET scan as a new service.. PubMed. 11(1). 11–4. 1 indexed citations

16.

Wilder, Richard B., Chul S. Ha, James D. Cox, et al.. (2002). Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer. 94(5). 1532–1537. 79 indexed citations

17.

Liebross, Robert H., Chul S. Ha, James D. Cox, et al.. (1998). Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. International Journal of Radiation Oncology*Biology*Physics. 41(5). 1063–1067. 117 indexed citations

18.

Seong, Chu‐Myong, Kay Delasalle, Kimberly Hayes, et al.. (1998). Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology. 101(1). 189–194. 108 indexed citations

19.

Weber, Donna, Meletios Α. Dimopoulos, Frank A. Sinicrope, & Raymond Alexanian. (1995). VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma. Leukemia & lymphoma. 19(1-2). 159–163. 5 indexed citations

20.

Daliani, Danai, Donna Weber, & Raymond Alexanian. (1995). Light‐heavy chain deposition disease progressing to multiple myeloma. American Journal of Hematology. 50(4). 296–298. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact